Similar articles

• Histopathological findings in heart transplant patients under tacrolimus-mycophenolate mofetil versus cyclosporine microemulsion-azathioprine.

  Sgrosso JL, Ferrer J, Araujo G, Romeo L, Parisi C, Vázquez MC. Sgrosso JL, et al. Transplant Proc. 2002 Feb;34(1):115-6. doi: 10.1016/s0041-1345(01)02695-1. Transplant Proc. 2002. PMID: 11959214 No abstract available.
• Improved survival after lung transplantation in patients treated with tacrolimus/mycophenolate mofetil as compared with cyclosporine/azathioprine.

  Izbicki G, Shitrit D, Aravot D, Sulkes J, Saute M, Sahar G, Kramer MR. Izbicki G, et al. Transplant Proc. 2002 Dec;34(8):3258-9. doi: 10.1016/s0041-1345(02)03691-6. Transplant Proc. 2002. PMID: 12493439 Clinical Trial. No abstract available.
• Mycophenolate mofetil reduces anti-HLA antibody production and cellular rejection in heart transplant recipients.

  Lietz K, John R, Schuster M, Ankersmit J, Burke E, Suciu-Foca N, Edwards N, Mancini D, Itescu S. Lietz K, et al. Transplant Proc. 2002 Aug;34(5):1828-9. doi: 10.1016/s0041-1345(02)03092-0. Transplant Proc. 2002. PMID: 12176593 No abstract available.
• New immunosuppressive agents in clinical use: mycophenolate mofetil and tacrolimus.

  Hunt SA. Hunt SA. Cardiol Rev. 2000 May-Jun;8(3):180-4. Cardiol Rev. 2000. PMID: 11174892 Review.
• Overview of transplantation immunology and the pharmacotherapy of adult solid organ transplant recipients: focus on immunosuppression.

  Bush WW. Bush WW. AACN Clin Issues. 1999 May;10(2):253-69; quiz 304-6. doi: 10.1097/00044067-199905000-00011. AACN Clin Issues. 1999. PMID: 10578712 Review.